63758-12-3

Basic information

• Product Name: 2,3-DIHYDRO-1,4-BENZODIOXINE-6-SULFONYL CHLORIDE
• Synonyms: TIMTEC-BB SBB010128;AKOS BBS-00003080;2,3-DIHYDRO-1,4-BENZODIOXINE-6-SULFONYL CHLORIDE;2,3-DIHYDRO-1,4-BENZODIOXINE-6-SULPHONYLCHLORIDE;2,3-DIHYDRO-BENZO[1,4]DIOXINE-6-SULFONYL CHLORIDE;1,4-BENZODIOXIN-6-SULFONYL CHLORIDE, 2,3-DIHYDRO-;BUTTPARK 95\50-61;CHEMBRDG-BB 4902369
• CAS NO: 63758-12-3
• Molecular Formula: C₈H₇ClO₄S
• Molecular Weight: 234.66
• Product Categories: SULFONYLHALIDE
• Mol File: 63758-12-3.mol

Chemical Properties

• Melting Point: 66 °C
• Boiling Point: 344.2 °C at 760 mmHg
• Flash Point: 162 °C
• Appearance: /
• Density: 1.513 g/cm³
• Vapor Pressure: 0.000133mmHg at 25°C
• Refractive Index: 1.573
• Storage Temp.: Inert atmosphere,Room Temperature
• Sensitive: Moisture Sensitive
• CAS DataBase Reference: 2,3-DIHYDRO-1,4-BENZODIOXINE-6-SULFONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-DIHYDRO-1,4-BENZODIOXINE-6-SULFONYL CHLORIDE(63758-12-3)
• EPA Substance Registry System: 2,3-DIHYDRO-1,4-BENZODIOXINE-6-SULFONYL CHLORIDE(63758-12-3)

Safety Data

• Hazard Codes: C,Xi
• Statements: 34
• Safety Statements: 26-36/37/39-45-36/37
• RIDADR: 3261
• WGK Germany: 3
• HazardClass: 8
• Hazardous Substances Data: 63758-12-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry:
2,3-Dihydro-1,4-benzodioxine-6-sulfonyl chloride is used as a reagent for the formation of various organic structures and compounds. Its unique chemical properties make it a valuable tool in the synthesis of a wide range of organic molecules.
Used in Chemical Synthesis Industry:
In the chemical synthesis industry, 2,3-Dihydro-1,4-benzodioxine-6-sulfonyl chloride is used as a key component in the production of various substances. Its role in the synthesis process is crucial for the creation of a multitude of chemical products.
Used in Advanced Chemical Synthesis Operations:
2,3-Dihydro-1,4-benzodioxine-6-sulfonyl chloride is employed as a valuable chemical tool in advanced chemical synthesis operations. Its reactivity and sensitivity make it an essential component in the development of complex organic compounds, despite the need for careful handling and storage to avoid potential risks.

InChI:InChI=1/C8H7ClO4S/c9-14(10,11)6-1-2-7-8(5-6)13-4-3-12-7/h1-2,5H,3-4H2

Upstream product

• 493-09-4 benzo-1,4-dioxane 
• 274-09-9 Methylenedioxybenzene 
• 107-06-2 1,2-dichloro-ethane 

Downstream Products

• 1203493-94-0 1-(2,6-difluorophenylsulfonyl)-4-(2,3-dihydrobenzo[b][1,4]dioxin-6-ylsulfonyl)-1,4-diazepane 
• 1203493-96-2 N-(2-(2,6-difluorophenylsulfonamido)ethyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-sulfonamide 
• 1203493-98-4 N-(3-(2,6-difluorophenylsulfonamido)propyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-sulfonamide 
• 1203494-00-1 N-(4-(2,6-difluorophenylsulfonamido)butyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-sulfonamide 
• 1203494-03-4 N-(5-(2,6-difluorophenylsulfonamido)pentyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-sulfonamide 
• 314260-32-7 C₁₅H₁₃NO₆S 

Relevant articles and documents

Sulfonamide inhibitors of aspartyl protease

The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical

Bispiperidines as antithrombotic agents

Novel compounds which are inhibitors of the binding of fibrinogen to the Gp IIb/IIIa platelet receptors, and which can be used therepeutically as antithrombotic agents

alpha 1a adrenergic receptor antagonists

This invention relates to novel compounds, their synthesis and use as selective alpha 1a adrenergic receptor antagonists. One application of the compounds is in the treatment of benign prostatic hyperplasia. The compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

Alpha 1a adrenergic receptor antagonists

This invention relates to novel compounds, their synthesis and use as selective α 1a adrenergic receptor antagonists. One application of the compounds is in the treatment of benign prostatic hyperplasia. The compounds are selective in their ability to relax smooth muscle tissue enriched in the α 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

Alpha IC adrenergic receptor antagonists

This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha-1C adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hypertrophy. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha1C receptor subtype without at the same time inducing orthostatic hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

Synthesis of bicyclic aromatic sulfonic acids sulfonyl chlorides and sulfonamides

This invention provides a novel process for the synthesis of bicyclic aromatic sulfonic acids employing reacting a bicyclic aromatic compound with sulfur trioxide-N,N-dimethylformamide complex in the presence of a water miscible, non-reactive solvent. The resulting sulfonic acid may be converted into the corresponding sulfonyl halide by the reaction with a thionyl halide. This invention further provides a novel process for the synthesis of bicyclic aromatic sulfonamides employing the reaction conditions described supra followed by an ammonolysis or amination.